Zacks Research Estimates Novavax’s Q2 Earnings (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) – Research analysts at Zacks Research raised their Q2 2025 earnings per share estimates for Novavax in a report released on Tuesday, January 28th. Zacks Research analyst S. Ganoria now anticipates that the biopharmaceutical company will post earnings of $0.44 per share for the quarter, up from their prior forecast of $0.39. The consensus estimate for Novavax’s current full-year earnings is ($1.31) per share. Zacks Research also issued estimates for Novavax’s Q2 2026 earnings at $0.07 EPS and FY2026 earnings at $0.39 EPS.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.07. The company had revenue of $84.51 million during the quarter, compared to analyst estimates of $65.80 million. During the same quarter in the prior year, the company posted ($1.26) earnings per share. The business’s revenue was down 54.8% compared to the same quarter last year.

A number of other brokerages also recently issued reports on NVAX. HC Wainwright reaffirmed a “buy” rating and set a $19.00 price target on shares of Novavax in a report on Tuesday, December 10th. B. Riley reaffirmed a “buy” rating and set a $26.00 price target (up previously from $23.00) on shares of Novavax in a research report on Thursday, October 10th. Finally, Jefferies Financial Group cut their target price on shares of Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $17.83.

Novavax Stock Performance

NASDAQ NVAX opened at $9.01 on Thursday. Novavax has a one year low of $3.53 and a one year high of $23.86. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -3.99 and a beta of 2.07. The firm has a 50 day simple moving average of $8.81 and a 200-day simple moving average of $10.84.

Institutional Trading of Novavax

Hedge funds and other institutional investors have recently bought and sold shares of the company. Amalgamated Bank grew its holdings in Novavax by 26.9% in the 2nd quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 1,036 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Novavax by 38.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 1,598 shares during the period. Victory Capital Management Inc. raised its position in shares of Novavax by 12.0% in the 3rd quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 2,072 shares during the period. Creative Planning grew its position in Novavax by 12.5% during the second quarter. Creative Planning now owns 24,143 shares of the biopharmaceutical company’s stock valued at $306,000 after acquiring an additional 2,692 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Novavax by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,965 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 3,174 shares in the last quarter. 53.04% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Novavax news, Director James F. Young sold 5,400 shares of Novavax stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total transaction of $43,200.00. Following the completion of the transaction, the director now owns 51,760 shares in the company, valued at approximately $414,080. The trade was a 9.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Rachel K. King sold 4,150 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $9.02, for a total value of $37,433.00. Following the completion of the sale, the director now directly owns 14,770 shares in the company, valued at approximately $133,225.40. The trade was a 21.93 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 14,150 shares of company stock valued at $119,641. Corporate insiders own 1.00% of the company’s stock.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.